

Cover Story
By Matthew Bin Han Ong
The graphs make it seem so simple:Doctors learn about a new therapy. They start to prescribe it. A standard of care is born. In a matter of months.
In Brief
Funding Opportunities
Drugs & Targets


Trending Stories
- Columbia’s cancer center becomes collateral damage in Trump’s war on antisemitism
- What Trump’s pick of RFK Jr. means for cancer: Epidemics, HPV, stunted research
Former FDA Commissioner Scott Gottlieb expresses “deep concerns” - Caught in the crossfire: The critical threats facing cancer centers, research, and patient care
- Kennedy announces massive cuts, centralization at HHS—NCI and FDA hit
Also this week: Columbia yields, Makary and Bhattacharya confirmed, tariffs on pharmaceuticals, and more changes impacting oncology - Pediatric cancer research cut from spending legislation at last minute
Republicans quietly removed hard-won pediatric cancer bills - DOD cancer research programs face 57% funding cut in year-long continuing resolution
Pancreatic, lung, kidney cancer research programs eliminated